Weerawat ManosuthiSukanya ChimsuntornSupeda ThongyenSamruay NilkamhangSomnuek SungkanuparphThailand Ministry of Public HealthMahidol UniversityBamrasnaradura Infectious Diseases Institute2018-05-032018-05-032011-03-01Journal of the International Association of Physicians in AIDS Care. Vol.10, No.2 (2011), 105-11015570886154510972-s2.0-79953146928https://repository.li.mahidol.ac.th/handle/123456789/12075Objective: To compare treatment outcomes between the regimens of single-boosted protease inhibitor (PI) and double-boosted PIs for the salvage therapy in patients who failed nonnucleoside reverse transcriptase inhibitor (NNRTI)-based regimens. Methods: A total of 64 patients from 2 cohorts, 40 in twice daily ritonavir-boosted lopinavir (LPV/r) at 400/100 mg plus lamivudine (3TC) and 24 in once daily ritonavir-boosted atazanavir and saquinavir (ATV/SQV/r) at 300/1600/100 mg/d, were studied. Results: At 48 weeks, 30 (75%) patients in LPV/r group and 20 (83%) patients in ATV/SQV/r group achieved HIV-1 RNA at < 400 copies/mL (P =.790). In all, 24 (60%) and 16 (67%) achieved HIV-1 RNA at < 50 copies/mL (P =.541). Low-level viral rebound (51-400 copies/mL) was found in 6 (15%) in LPV/r group and 4 (17%) in ATV/SQV/r group (P = 1.000). Medians CD4 counts were 336 cells/mm 3 and 330 cells/mm 3 in the corresponding groups (P = 0.937). Conclusion: No additional benefit is found with double-boosted PIs compared to single-boosted PI in terms of treatment responses in HIV-infected patients failing NNRTI-based regimen. © The Author(s) 2011.Mahidol UniversityImmunology and MicrobiologyMedicineArticleSCOPUS10.1177/1545109710383335